◀ Back to CD8A

CD8A — EXO1

Text-mined interactions from Literome

Hao et al., Immunology 2007 (Lung Neoplasms) : The mDC ( EXO ) could more strongly stimulate OVA-specific CD8 ( + ) T-cell proliferation in vitro and in vivo, and more efficiently induce OVA-specific cytotoxic T-lymphocyte responses, antitumour immunity and CD8 ( + ) T-cell memory in vivo than EXO ( OVA ) and DC ( OVA )
Xie et al., Cancer Biother Radiopharm 2010 (Multiple Myeloma) : Taken together, we demonstrate that EXO ( TNF-a ) released by engineered J558 ( TNF-a ) tumor cells more efficiently stimulate tumor antigen P1A-specific CD8 ( + ) CTL responses and antitumor immunity than EXO ( IL-2 ) and EXO ( IFN-gamma ) released by engineered J558 ( IL-2 ) and J558 ( IFN-gamma ) tumor cells
Zhang et al., Cell Mol Immunol 2011 (Autoimmune Diseases...) : OVA-specific CD4 ( + ) T-cell EXO from OTII mice, but not ConA stimulated polyclonal CD4 ( + ) T-cell EXO from wild-type C57BL/6 mice inhibited DC ( OVA ) -stimulated in vitro CD4 ( + ) T-cell proliferation and in vivo CD8 ( + ) cytotoxic T lymphocyte ( CTL ) responses and antitumor immunity against OVA expressing B16 melanoma BL6-10 ( OVA ) cells